Pharmaceuticals

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2025–2029: Unveiling Growth Developments with the Latest Updates

September 23, 2025 by Marketing Posting

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Big Is The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Today And What Is Its Future Size?#_x000D_

The market size of treatments for chronic obstructive pulmonary disease (copd) has seen consistent growth in recent times. It’s expected to rise from $20.84 billion in 2024 to $21.73 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.3%. The expansion during the historical period is attributed to factors like the smoking epidemic and tobacco intake, innovations in inhalation therapies, early diagnostic procedures and awareness programs, government-driven initiatives for respiratory wellness, and research and development within the field of pulmonology._x000D_

_x000D_

The market for the treatment of chronic obstructive pulmonary disease (copd) is predicted to experience robust growth in the coming years. The market is anticipated to reach a value of “$27.22 billion by 2029, registering a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period is credited to factors such as personalized medicine and biomarker research, biologic therapies, and targeted interventions. Other factors include concerns around air quality and environmental reasons, global initiatives aimed at quitting smoking, and collaborations for the development of new drugs. Key trends to lookout for during the forecast period encompass using digital health solutions for COPD management, biologic therapies, the advent of personalized medicine, combination therapies, inhalers, early diagnosis, intervention, and pulmonary rehabilitation programs._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp_x000D_

_x000D_

#What Market Forces Are Contributing To The Growth Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?#_x000D_

The escalating incidence of lung disease is anticipated to stimulate the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease refers to any disorder that hampers the appropriate functioning of the lungs, and the most prevalent ones include asthma, COPD, and lung cancer. The primary aim of chronic obstructive pulmonary disease (COPD) treatment is to manage the disease by slowing down its progression, controlling symptoms, and averting lung damage with the help of inhalers and medications. For instance, as per the global initiative for Chronic obstructive lung disease (GOLD), a non-profit organization based in the US, around 3.2 million people die annually from chronic obstructive pulmonary disease (COPD), affecting roughly 200 million people. Additionally, asthma impacted 262 million individuals worldwide in 2022. Such numbers are projected to escalate in the future. Furthermore, the LUNGevity Foundation, another US-based non-profit organization, predicted that about 127,000 Americans will succumb annually to lung cancer in 2023. Hence, it is the rising incidence of lung disease which is propelling the growth of the chronic obstructive pulmonary disease (COPD) treatment market._x000D_

_x000D_

#What Are The Key Segment Trends Observed In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?#_x000D_

The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes_x000D_

2) By Type: Chronic Bronchitis, Emphysema_x000D_

3) By End-User: Hospitals, Clinics, Homecare Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)_x000D_

2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)_x000D_

3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids_x000D_

4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors_x000D_

5) By Mucokinetics: Expectorants, Mucolytics_x000D_

6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents_x000D_

_x000D_

#Which Disruptive Trends Are Driving Change Across The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?#_x000D_

The trend of product innovation is becoming increasingly prominent in the market for Chronic Obstructive Pulmonary Disease (COPD) treatment. Major firms in this market are turning their attention to creating novel products in order to maintain market relevance. For example, GlaxoSmithKline plc (GSK), a pharmaceutical and biotech company based in the UK, introduced the first single-inhaler triple treatment (SITT) for COPD patients in India, named Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) in April 2022. Used primarily as a preservation medication, Trelegy Ellipta is indicated for the prevention and treatment of Chronic Obstructive Pulmonary Disease (COPD) signs and symptoms in individuals aged 18 and over. It operates similarly to natural corticosteroid hormones, latching onto receptors on certain immune cells to suppress the immune response. Moreover, it aids in decreasing lung airway swelling, thus facilitating easier breathing._x000D_

_x000D_

#Who Are The Leading Companies Driving The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?#_x000D_

Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc. _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report_x000D_

_x000D_

#Which Region Is Forecasted To Lead The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In The Coming Years?#_x000D_

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_